HOME
PRODUCTS
COMPANY
CONTACT
FAQ
Research
Dictionary
Pharma
Sign Up
FREE
or
Login
Username:
Password:
Remember login
Login
Send password reminder...
BMY 21502
structure given in first source
Also Known As:
1-(1-(2-fluoromethyl)-4-pyrimidinyl)-4-piperidinylmethyl-2-pyrrolidinone; BMS-181168; BMY-21502; 2-Pyrrolidinone, 1-((1-(2-(trifluoromethyl)-4-pyrimidinyl)-4-piperidinyl)methyl)-
Networked:
6
relevant articles (
1
outcomes,
2
trials/studies)
Relationship Network
Bio-Agent Context: Research Results
Heterocyclic Compounds: 198
1-Ring Heterocyclic Compounds
Pyrimidines: 510
BMY 21502: 6
Pyrrolidines: 115
Pyrrolidinones: 162
BMY 21502: 6
Related Diseases
1.
Brain Hypoxia (Cerebral Hypoxia)
03/01/1993 - "
The protective effects of BMY-21502 (1-[[1-[2-(trifluoromethyl)-4-pyrimidinyl]-4-piperidinyl]methyl]-2- pyrrolidinone) against cerebral anoxia were investigated using various models in mice, in comparison with those of other cerebroactive drugs.
"
2.
Hypoxia (Hypoxemia)
09/01/1994 - "
BMS-181168 for protection of the human brain against hypoxia: double-blind, placebo-controlled EEG mapping studies.
"
03/01/1993 - "
Significant protection by BMY-21502 against moderate hypobaric hypoxia was observed at doses of 30 and 100 mg/kg, p.o.
"
03/01/1993 - "
Effects of BMY-21502 on anoxia in mice.
"
03/01/1993 - "
Oral administration of BMY-21502 (10-100 mg/kg) significantly prolonged the survival time in KCN (2.4 mg/kg, i.v.)-induced anoxia.
"
03/01/1993 - "
The anti-anoxic effect of BMY-21502 in the KCN-anoxia model was blocked by pretreatment with scopolamine.
"
3.
Brain Injuries (Brain Injury)
10/08/1993 - "
In the present study, we characterized alterations in the ability of rats to learn a novel task following lateral FP brain injury and examined the potential modulatory effects of the nootropic cognitive enhancer BMY-21502 on post-injury learning.
"
4.
Dementia (Dementias)
01/01/1992 - "
These results suggest that BMY 21502 is orally active over a broad range of doses, and lend further support for its potential as a therapeutic agent for the treatment of dementia.
"
01/01/1998 - "
The type of CNS effects produced by EGb (as established by HZI's CEEG psychotropic drug database) in elderly dementia patients were similar to those induced by tacrine responders as well as those seen after the administration of other "cognitive activators" (pramiracetam, vinpocetine, BMY-21502, suloctidil, and lisuride) and anti-dementia drugs approved in the United States or Europe (tacrine, donepezil, nimodipine, piracetam, and oxiracetam) from our database.
"
5.
Amnesia (Dissociative Amnesia)
03/01/1990 - "
BMY 21502 is a novel pyrrolidinone nootropic with demonstrated ability to reverse electroconvulsively induced amnesia in rodents.
"
Related Drugs and Biologics
1.
Pyrrolidinones (Pyrrolidones)
2.
Nootropic Agents (Nootropics)
3.
Tacrine (Cognex)
4.
Suloctidil
5.
Scopolamine (Hyoscine)
6.
Psychotropic Drugs (Psychoactive Drugs)
7.
Piracetam (Nootropil)
8.
Nimodipine (Modus)
9.
Lisuride
10.
Donepezil (Aricept)
Related Therapies and Procedures
1.
Oral Administration